2型糖尿病亚组特征及其与种族和临床结局的关联:基于东伦敦数据库的英国真实世界研究
与MARD相比,SHD亚组长期血糖控制最差、启动降糖治疗最快(HR 2.02,95%CI 1.76-2.32)、微血管并发症风险最高(HR 1.38,95%CI 1.28-1.49);MOD亚组大血管并发症风险最高(HR 1.50,95%CI 1.23-1.82)。亚组差异在治疗启动方面白人组最明显,在血管并发症方面黑人组最明显。
要点
- 在初级保健真实世界多族裔人群中,诊断时可识别出MARD、MOD和SHD三个2型糖尿病亚组。
- SHD亚组血糖控制最差、治疗启动最快、微血管并发症风险最高。
- MOD亚组大血管并发症风险最高,亚组差异因种族而异。
核心结论
- 在常规真实世界多族裔初级保健人群中,诊断时即可识别出具有临床意义的2型糖尿病亚组,可能为制定分层初级保健路径和改善医疗资源分配提供实用手段。
研究设计与样本
- 采用潜在类别分析,基于诊断时的年龄、性别、糖化血红蛋白和体重指数推导亚组。
- 使用多变量Cox比例风险回归估计治疗启动时间和血管结局。
主要发现
- 复制出既往描述的轻度年龄相关糖尿病(MARD)和轻度肥胖相关糖尿病(MOD)两个亚组,并识别出第三个亚组严重高血糖糖尿病(SHD)。
- 与MARD相比,SHD亚组长期血糖控制最差、启动降糖治疗最快(HR 2.02,95%CI 1.76-2.32)、微血管并发症风险最高(HR 1.38,95%CI 1.28-1.49)。
- MOD亚组大血管并发症风险最高(HR 1.50,95%CI 1.23-1.82)。
- 治疗启动的亚组差异在白人组最明显,血管并发症的亚组差异在黑人组最明显。
关键数值与推荐
- 亚组推导基于诊断时的年龄、性别、糖化血红蛋白和体重指数进行潜在类别分析。
- 与MARD相比,SHD亚组启动降糖治疗的HR为2.02(95%CI 1.76-2.32),微血管并发症HR为1.38(95%CI 1.28-1.49)。
- MOD亚组大血管并发症HR为1.50(95%CI 1.23-1.82)。
临床怎么用
- 在初级保健中可利用诊断时的常规数据识别2型糖尿病亚组,辅助分层管理。
- 对严重高血糖糖尿病(SHD)亚组应加强血糖监测和微血管并发症筛查。
- 对轻度肥胖相关糖尿病(MOD)亚组应关注大血管并发症风险评估。
- 亚组差异因种族而异,临床管理需考虑族裔背景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Subgroups of type 2 diabetes (T2DM) have been well characterised in experimental studies. It is unclear, however, whether the same approaches can be used to characterise T2DM subgroups in UK primary care populations and their associations with clinical outcomes. AIM: To derive T2DM subgroups using primary care data from a multi-ethnic population, evaluate associations with glycaemic control, treatment initiation, and vascular outcomes, and to understand how these vary by ethnicity. DESIGN AND SETTING: An observational cohort study in the East London Primary Care Database from 2008 to 2018. METHOD: Latent-class analysis using age, sex, glycated haemoglobin, and body mass index at diagnosis was used to derive T2DM subgroups in white, South Asian, and black groups. Time to treatment initiation and vascular outcomes were estimated using multivariable Cox-proportional hazards regression. RESULTS: In total, 31 931 adults with T2DM were included: 47% South Asian (n = 14 884), 26% white (n = 8154), 20% black (n = 6423). Two previously described subgroups were replicated, 'mild age-related diabetes' (MARD) and 'mild obesity-related diabetes' (MOD), and a third was characterised 'severe hyperglycaemic diabetes' (SHD). Compared with MARD, SHD had the poorest long-term glycaemic control, fastest initiation of antidiabetic treatment (hazard ratio [HR] 2.02, 95% confidence interval [CI] = 1.76 to 2.32), and highest risk of microvascular complications (HR 1.38, 95% CI = 1.28 to 1.49). MOD had the highest risk of macrovascular complications (HR 1.50, 95% CI = 1.23 to 1.82). Subgroup differences in treatment initiation were most pronounced for the white group, and vascular complications for the black group. CONCLUSION: Clinically useful T2DM subgroups, identified at diagnosis, can be generated in routine real-world multi-ethnic populations, and may offer a pragmatic means to develop stratified primary care pathways and improve healthcare resource allocation.
引用
- Mathur R, Hull SA, Hodgson S, et al. Characterisation of type 2 diabetes subgroups and their association with ethnicity and clinical outcomes: a UK real-world data study using the East London Database. Br J Gen Pract. 2022. PMID: 35577589. doi:10.3399/BJGP.2021.0508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。